About
Aqemia, founded in 2019 in Paris, France, uses generative AI and quantum physics to discover cancer drugs, differentiating itself by not requiring experimental chemistry data to train its models during the design phase.
Technology & BusinessWhat · How · Which stage
Research Areas生命科学医药MediumEvidence
使用生成式AI和量子物理学来发现癌症药物；设计阶段不需要化学实验数据训练，用基于量子和统计物理的计算在内部生成数据
Source：Official site · Updated 2026-09-10 · View source
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Funding history
- 2024-12New funding round$38M
Investors · Bpifrance, Cathay, Eurazeo, Wendel, Elaia PartnersSource · SVTR Weekly #083
- 2024-02Series A$33M
Investors · Wendel, Wendel Growth, Bpifrance, Eurazeo, Elaia PartnersSource · SVTR Weekly #038
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Aqemia
Cancer drug discovery using generative AI and quantum physics
Undisclosed · $71M · 2024-12
$71M
United States
BusinessLatest roundTotal raisedDate- Aureka Biotechnologies
AuraIDE™, a platform for generative antibody drug discovery and functional antibody design
Series B · $200M · 2026-08
$200M - Evozyne
Generative AI platform for drug discovery and development
Undisclosed · $81M · 2023-09
$81M - Ten63 Therapeutics
Applies generative AI models to drug discovery and development
$54M · 2026-03
$54M
China
BusinessLatest roundTotal raisedDate- Insilico Medicine
AI drug discovery company that uses generative models for target discovery and molecular design, and has advanced multiple drug candidates into clinical trials
Series D+ · $210M · 2025-03
$210M - Deep Pharma
AI-driven drug discovery and clinical development platform
Series D+ · $200M · 2026-03
$200M - Drug Farm
Drug developer using genetics and AI to discover first-in-class targets
Series D+ · $55M · 2026-07
$55M
Europe
BusinessLatest roundTotal raisedDate- Turbine
Uses AI to simulate biological experiments, accelerating drug discovery and translational research
Series B · $25M · 2026-03
$25M - Sightera Biosciences
AI-native drug discovery: patient-derived disease models and generative AI to design small-molecule cancer/fibrosis therapies
Pre-Seed · $3M · 2026-07
$3M - Causaly
AI platform that helps researchers accelerate drug development and testing
Series B · $60M · 2023-07
$60M
Other / unspecified
BusinessLatest roundTotal raisedDate- Galux
AI plus physics-based protein/antibody design platform (GaluxDesign) for drug discovery
Series B · $58M · 2026-02
$58M - 深度细胞
Combines AI with multiscale molecular physics to build a "virtual cell world model" for disease mechanism discovery and drug design
Seed · $14M · 2026-08
$14M - Miles Wang 新公司
Develops AI models for drug discovery
—
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.